In SURPASS-2, which compared tirzepatide to semaglutide (a GLP-1 receptor agonist) in patients taking metformin, tirzepatide 5 mg, 10 mg, and 15 mg doses achieved mean HbA1c reductions of 2.01%, 2.24%, and 2.30% respectively from baseline, compared to 1.86% with semaglutide 1 mg
Patients may be eligible for financial assistance programs which can help manage the costs associated with Tirzepatide
Track your response to treatment, including appetite patterns, food intake, weight changes, and any side effects
When choosing a powder for GLP-1-friendly breakfasts: Think about how it mixes with your favorite breakfast foods Decide whether you prefer flavored or unflavored options Consider your texture preferences Look for simple ingredient lists if that matters to you The best choice depends on your personal preference and how the powder integrates into meals you enjoy